InvestorsHub Logo
Followers 480
Posts 60396
Boards Moderated 18
Alias Born 09/20/2001

Re: lattices post# 302

Sunday, 02/26/2017 11:46:00 AM

Sunday, February 26, 2017 11:46:00 AM

Post# of 1319
Thanks for that excellent summary - I'd seen the comments on S.A. and your analysis concurs with my line of thinking.

I have 50% respiratory capacity myself and I can see where Oliceridine could be much better in an aging population.

I rely strongly on charts and my experience tells me that events like this need to work out with time. I don't disagree with your buy and hold strategy but I will be watching for an entry. Hopefully this will be after another stock that fell from $60 to $4 in a similar situation matures and I can roll some profits in here.

Since a major part of the valuation was in regard to it being non addictive. From what I've read on message boards it seems that it was apparent to some that this would not be happening because of the receptor acted upon.

This is above my level of expertise, but I guess the question should also be asked, do any of the possible competitors to Oliceridine have the potential to be non-addictive?






In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TRVN News